Table of Contents
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):August 26, 2004
Idenix Pharmaceuticals, Inc.
Delaware | 000-49839 | 45-0478605 | ||||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||
60 Hampshire Street | ||||||
Cambridge, MA | 02139 | |||||
| (Address of principal executive offices) | (Zip Code) | |||||
Registrant’s telephone number, including area code:(617) 995-9800
| Item 2.02 Results of Operations and Financial Condition | ||||||||
| SIGNATURE | ||||||||
| EXHIBIT INDEX | ||||||||
| EX-99.1 PRESS RELEASE DATED AUGUST 26, 2004 | ||||||||
Table of Contents
Item 2.02 Results of Operations and Financial Condition
On August 26, 2004, Idenix Pharmaceuticals, Inc. issued a press release announcing its financial results for the second quarter and six months ended June 30, 2004. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Form 8-K.
The information in this Form 8-K and the Exhibit attached hereto is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
2
Table of Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 26, 2004 | IDENIX PHARMACEUTICALS, INC. | |||
| By: | /s/ David A. Arkowitz | |||
| David A. Arkowitz | ||||
| Chief Financial Officer and Treasurer | ||||
3